

ORIGINAL RESEARCH ARTICLE

RUNNING HEAD: Physical activity and incident CVD in women with novel risk factors

TITLE: Association between physical activity and risk of incident cardiovascular disease in women with novel risk factors: evidence from the UK Biobank cohort

Authors: Zhaleh Ataei^{1,2}, Leah Wright^{1,2}, Sergio Ruiz-Carmona^{1,3}, Erin J Howden^{1,2}

Affiliations:

¹Baker Heart and Diabetes Institute, Melbourne, Australia

²Baker Department of Cardiometabolic Health, The University of Melbourne

³Centre for Health Analytics, Melbourne Children's Campus, Melbourne, Australia

Corresponding Author

Dr Erin J Howden

Cardiometabolic Health and Exercise Physiology Laboratory

Baker Heart and Diabetes Institute

75 Commercial Road

Melbourne, 3004, Australia

Email: erin.howden@baker.edu.au

1 **ABSTRACT**

2 **Background:** Previous evidence demonstrates an increased risk of incident cardiovascular
3 disease (CVD) in women with early menopause and/or adverse pregnancy outcomes. It also
4 suggests an inverse association between physical activity and risk of incident CVD. However,
5 this association in women with novel risk factors have not been evaluated. Therefore, we
6 aimed to address this hypothesis.

7 **Methods:** We explored the data of 253,300 women without a history of CVD or life limiting
8 conditions from the UK Biobank cohort, we further stratified women with a history of early
9 menopause and/or complicated pregnancy to investigate how the risks affect indent CVD in
10 women. We defined early menopause as any history of natural or surgical (bilateral
11 oophorectomy) menopause < 47 years and adverse pregnancy outcomes as a history of
12 gestational diabetes, hypertensive disorders of pregnancy, stillbirth or \geq two miscarriages. We
13 then classified women into three categories of physical activity based on their responses to
14 the International Physical Activity Questionnaire. Women with a total MET-min/week of \geq
15 3000, \geq 600 and < 600 were categorised into high, moderate, and low levels of physical
16 activity, respectively. We also assessed the dose-response interaction between physical
17 activity and risk of incident CVD (heart failure (HF), arrhythmia, coronary heart disease
18 (CHD), and stroke) in our population and adjusted all the models for potential CVD risk
19 factors.

20 **Results:** During a median follow-up of 13 years, we found a significant increased risk of
21 incident HF, arrhythmia and CHD in women with early menopause/complicated pregnancy,
22 compared to women without these risk factors. Higher levels of physical activity reduced the
23 risk of incident HF (HR 0.81, 95% CI 0.67 0.97) and arrhythmia (HR 0.84, 95% CI 0.75
24 0.94), compared to a low levels. Moreover, a moderate level of physical activity attenuated

25 the risk of incident arrhythmia (HR 0.82, 95% CI 0.74 0.92). However, no significant
26 associations were found between physical activity risk of incident stroke or CHD.

27 **Conclusion:** Our study indicates that higher levels of PA significantly attenuate the risk of
28 HF and arrhythmia in women with novel risk factors and should be recommended to women
29 to reduce their increased risk of CVD.

30

31 **Keywords:** pregnancy, menopause, pregnancy complications, primary prevention, exercise,
32 cardiovascular disease

33

34

35

36

37

38

39 INTRODUCTION

40 Cardiovascular disease (CVD) is the most common cause of mortality among women¹.
41 Despite recognition that gender and sex are important drivers of CVD risk, there remains an
42 unmet need to understand what the female specific drivers of CVD outcomes and potential
43 impacts of preventative approaches are. Some traditional risk factors, including diabetes,
44 smoking and obesity, put women at higher risk of developing CVD than men¹⁻³. The risk of
45 developing coronary heart disease (CHD) conferred by obesity and cigarette smoking is
46 greater in women compared to men by 18% and 25%, respectively⁴. Moreover, women with
47 diabetes are at 44% higher risk of incident CVD compared to men.² In addition, some
48 unmodifiable or less modifiable stages in women's lives, like early menopause and
49 complicated pregnancy, make them even more vulnerable to CVD.^{5,6} According to previous
50 studies, complicated pregnancy and early menopause affect up to 25%⁷ and ~10%⁸ of
51 women, respectively. However, currently there is poor recognition of these risk factors to
52 overall CVD risk stratification and limited evidence of effective prevention approaches.

53 Physical activity is the cornerstone of CVD prevention. It reduces the risk of incident
54 CVD and attenuates the harmful effects of other adverse behaviours, such as inappropriate
55 sleep time or high sedentary behaviour, on cardiovascular health.⁹⁻¹¹ Despite additional risk
56 factors in women, they tend to be less active and are more sedentary than men (33.2%
57 inactivity in women vs 29.9% in men)². Physical activity is critical to preventing CVD in this
58 large population. However, the effects of physical activity on the risk of incident CVD in
59 women with novel risk factors, including early menopause and complicated pregnancy, has
60 yet to be explored. Determining if physical activity is beneficial in this setting will have
61 important public health implications, since engaging in physical activity is among the most
62 simple and accessible methods to prevent CVD. Our aims were two-fold: firstly, to determine
63 how female-specific risk factors influenced rates of CVD in women in the UK Biobank

64 cohort. Secondly, to understand how physical activity modifies the increased risk of CVD in
65 women with novel risk factors and to explore what the ideal level of physical activity is
66 required to prevent developing CVD in this population. We hypothesised that physical
67 activity would be a modifier of CVD outcomes in women with female-specific risk factors.

68 **METHODS**

69 **Study design:** The UK Biobank is a large prospective cohort study involving over 500,000
70 participants enrolled from 2006-2010 (Northwest Multicentre Research Ethics Committee
71 (11/NW/0382), Resource number 55469)). At baseline, participants were aged 40-69 years
72 old and assessed in various centres across England, Wales and Scotland and were followed up
73 for different outcomes through linkages to national datasets.¹² Women with a previous
74 history of CVD (N=8813), including heart failure (HF), coronary heart disease (CHD),
75 arrhythmia, ischemic stroke, or any congenital heart disease were excluded from the study
76 (Figure 1). We also excluded women with conditions that reduced their projected life
77 expectancy to less than three years (Alzheimer's disease, kidney failure, chronic obstructive
78 pulmonary disease (COPD), and liver failure, N=3420). Information regarding the exact
79 conditions and their related ICD-10 codes can be found in the supplementary section. The
80 remaining 253,300 women were included in our study. Our analysis was divided into two
81 stages to assess our aims and hypothesis: 1) To assess how novel risk factors impact the risk
82 of developing CVD in women; and 2) To investigate how engaging in different levels of PA
83 interacts with incident CVD in women with novel risk factors. For our second stage, we
84 excluded women without a history of early menopause or complicated pregnancy in addition
85 to those with missing physical activity data or responses that were considered as outliers
86 according to guidelines¹³, giving us a final sample size of 40,952 women (Figure 1).

87

88 **Physical Activity Assessment**

89 Physical activity was assessed according to the participants' self-reported responses to the
90 International Physical Activity Questionnaire (IPAQ)¹⁴. Individuals responded to questions
91 regarding the amount and type of physical activity they engaged in the last seven days,
92 including leisure time, domestic and gardening, as well as work and transport-related physical
93 activity. A "high level" of physical activity was defined as achieving ≥ 3000 MET-min/week
94 with a combination of different intensity activities or achieving ≥ 1500 MET-min/week with
95 vigorous intensity activities. A moderate level of physical activity was defined as engaging in
96 vigorous-intensity physical activity of ≥ 20 min/day for \geq three days/week or doing a
97 moderate-intensity activity for \geq five days/week and/or walking of ≥ 20 min/day or achieving
98 ≥ 600 MET-min/week by doing a combination of different intensity activities.

99

100 **Novel Risk factors:**

101 We defined novel risk factors as any history of early onset menopause (any natural or surgical
102 (bilateral oophorectomy) menopause earlier than 47 years) and/or complicated pregnancy
103 (positive history of one or more of the following: gestational diabetes, hypertensive disorders
104 of pregnancy, stillbirth, and/or two or more miscarriages).^{6,15} Data regarding the number of
105 miscarriages and stillbirths and the age of menopause were extracted from the self-reported
106 questionnaires. Gestational diabetes was defined based on self-reported data and/or related
107 ICD-10 codes. The data regarding hypertensive disorders of pregnancy were determined by
108 ICD-10 codes.

109

110 **Endpoints:**

111 We defined the primary endpoints of this study as diagnosis of HF, CHD, arrhythmia, or
112 ischemic stroke. All the events were reported using ICD-10 codes based on the data from
113 hospitals/clinics (see table S1 supplementary material for complete list). If more than one

114 event occurred to a participant, we only counted the first one. The number of events for each
115 endpoint followed this rule, and only one event per participant was counted. Time to event for
116 each participant was taken from the date of birth and censored at the date associated with the
117 development of each endpoint or date of death or the date of their last follow-up session,
118 whichever came first.

119

120 **Covariates:**

121 We adjusted the results for CVD risk factors, including age, smoking status, obesity, alcohol
122 consumption, diabetes mellitus, hypertension, dyslipidaemia, and history of cancer. Data
123 regarding the smoking status and alcohol intake frequency (how many times per day, week,
124 or month) were obtained from self-reported questionnaires. Obesity was defined as BMI \geq
125 30, calculated based on the participants' responses to height and weight at their baseline
126 visits. Diagnosis of hypertension, diabetes, dyslipidaemia, and cancer were defined by at least
127 one of the related ICD-10 codes (supplementary section).

128

129 **Statistical analysis:**

130 We used Cox proportional hazard models to estimate the hazard ratios (HRs) and 95%
131 confidence intervals (CIs) for incident CVD among women with and without novel risk
132 factors. To determine how different levels of physical activity attenuate the risk of incident
133 CVD we compared the effects of moderate and high levels of physical activity on the risk of
134 incident CVD to the low-level physical activity in women with novel risk factors. Cox
135 proportional hazard models were used to calculate the new hazard ratios and 95% confidence
136 intervals. We evaluated the relationship between physical activity as a continuous variables
137 and incident CVD with cubic spline models. We performed all statistical analyses with R
138 version 4.2.1.

139

140 **Study ethics:** The UK Biobank received ethical approval from the Northwest Multicentre
141 Research Ethics Committee (11/NW/0382). All participants gave written informed consent.
142 This study has been conducted using the UK Biobank Resource under application number
143 55469.

144 **RESULTS**

145 **Baseline characteristic.** Our study consisted of 253,300 women without a history of CVD or
146 life limiting conditions from the UK Biobank cohort. Baseline characteristics of the included
147 women are presented in table 1. The mean age at study entry was 57 ± 8 and 56 ± 8.0 years in
148 women with and without novel risk factors, respectively. Overall, women without novel risk
149 factors tended to be healthier, compared to women experiencing novel risk factors. Women
150 with novel risk factors were more likely to smoke, and have obesity, diabetes, hypertension,
151 dyslipidaemia, and increased incidence of past cancer. Of the 55,930 women with novel risk
152 factors, 23,627 had a history of complicated pregnancy, and 35,838 experienced early
153 menopause. There was overlap in novel risk factors in 3535 women. The median follow up
154 was 13 years in which there were 8833 incidence CVD events in women with novel risk
155 factors' arm and 21804 in women with no novel risk factors (table 2). The incidence of CVD
156 event rates were higher for each condition of interest among women with novel risk factors
157 compared to those without these risk factors.

158

159 **Interaction between novel risk factors and CVD outcomes**

160 In adjusted models, women with a history of early menopause had a significant increase in
161 the risk of incident HF (HR 1.16, 95% CI 1.08 1.25), CHD (HR 1.15, 95% CI 1.10 1.20),
162 arrhythmia (HR 1.09, 95% CI 1.04 1.14) and ischemic stroke (HR 1.18, 95% CI 1.07 1.29),
163 compared to women without this risk factor. Similarly, women with a history of complicated

164 pregnancy had a significantly higher risk of incident HF (HR 1.11, 95% CI 1.01 1.22), CHD
165 (HR 1.17, 95% CI 1.11 1.23) and arrhythmia (HR 1.07, 95% CI 1.01 1.13), compared to ones
166 without complicated pregnancy. However, there was no increased risk of ischemic stroke (HR
167 1.09, 95% CI 0.97 1.23) in the adjusted models.

168

169 **Physical activity and attenuation of heart failure risk in women with novel risk factors**

170 In the unadjusted models, there was a significant association between physical activity levels
171 and risk of incident HF demonstrating that both moderate (HR 0.69, 95% CI 0.59 0.82) and
172 high (HR 0.59, 95% CI 0.49 0.70) levels of physical activity reduce the risk of incident HF
173 significantly, compared to a low level of physical activity-. However, after adjusting for
174 confounders, only the association between a high level of physical activity and risk of
175 developing HF remained significant (HR 0.81, 95% CI 0.68 0.97) (Figure 2). Dose-response
176 models also showed a reduced risk of HF at a MET-min/week of 3000 (HR 1.10, 95% CI
177 0.94 1.28), compared to the baseline MET-min/week of 0 (HR 1.37, 95% CI 1.07 1.76)
178 (Figure 6A).

179

180 **Physical activity and attenuation of arrhythmia risk in women with novel risk factors**

181 In the unadjusted models, moderate (HR 0.69, 95% CI 0.62 0.77) and high (HR 0.67, 95% CI
182 0.60 0.75) levels of physical activity reduced the risk of arrhythmia, compared to low levels
183 of physical activity. After adjusting for confounders, we observed a non-linear association in
184 which the risk of arrhythmia decreased by 18% and 16% with moderate and high levels of
185 physical activity, respectively (Figure 3). The dose-response association, demonstrated a
186 lower risk of arrhythmia at MET-min/week of 3000 (HR 1.06, 95% CI 0.96 1.16) and 600
187 (HR 1.13, 95% CI 1.06 1.21), compared to 0 (HR 1.35, 95% CI 1.15 1.59) (Figure 6B).

188

189 **Physical activity and attenuation of coronary heart disease and stroke risk in women**
190 **with novel risk factors**

191 In the unadjusted models, higher levels of physical activity reduced the risk of incident CHD
192 compared to a low level of physical activity; however, adjusting the models for confounders
193 attenuated the effects (Figures 4). Similarly, the association between physical activity and
194 risk of incident stroke was consistent with that observed for CHD and after adjusting for
195 confounders, there was no statistically significant relationship between risk of incident stroke
196 and physical activity (Figures 5).

197

198 **Impact of traditional risk factors on CVD outcomes in women with novel risk factors**

199 In our multivariable models, traditional risk factors including hypertension and dyslipidaemia
200 were significantly associated with increased risk across all cardiovascular outcomes.
201 Hypertension demonstrated the strongest association with HF (HR 3.99, 95% CI 3.38 4.72),
202 arrhythmia (HR 2.94, 95% CI 2.67 3.24) and stroke (HR 3.01, 95% CI 2.45 3.69) compared
203 to other risk factors (Figures 2,3,5). While for CHD, dyslipidaemia (HR 3.90, 95% CI 3.58
204 4.24) emerged as the most significant determinant (Figure 4). Other factors, including
205 diabetes, history of cancer, smoking and obesity were also included in the analysis; however,
206 their associations with cardiovascular outcomes were less pronounced (Figure 2-5).

207

208 **DISCUSSION**

209 The principal new findings in the new study are as follows: women with a history of novel
210 CVD risk factors experience a higher frequency of CVD outcomes and have a higher burden
211 of traditional CV risk factors than women without novel risk factors. Further in this cohort of
212 higher risk women we found that higher levels of physical activity attenuated the risk of
213 incident HF and arrhythmia, but not CHD or ischemic stroke. These findings have important

214 implications for public health recommendations for physical activity and highlight a high-risk
215 group who could benefit from more targeted primary prevention strategies to increase
216 physical activity levels in this population. Indeed, our analysis of the dose effect of physical
217 activity on outcomes, identified that 3000 met minutes per week, which is consistent with
218 current physical activity guidelines, reduced the risk of HF and arrhythmia.

219

220 Both early menopause and complicated pregnancy are recognized contributors to an elevated
221 risk of CVD. Although a multitude of female-specific factors have been labelled differently in
222 many different studies, a consistent finding has been that female factors influence CVD
223 outcomes, primarily through hormonal changes and cardiometabolic risk factors.^{6,16} The
224 increased risk of CVD associated with early menopause is largely attributed to the premature
225 loss of estrogen, a protective factor against CVD¹⁶. Consistent with these established
226 mechanisms, our data showed that early menopause increased the risk of incident HF, CHD,
227 arrhythmia, and stroke by 16%, 15%, 9%, and 18%, respectively. Similarly, pregnancy
228 complications, including miscarriages ≥ 2 , stillbirth, gestational diabetes, and hypertensive
229 disorders of pregnancy, were associated with an increase in the risk of incident HF (11%),
230 CHD (17%), and arrhythmia (7%). Women with a history of complicated pregnancy have an
231 increased risk of developing CVD risk factors and later CVD¹⁷. The mechanism for this is
232 likely multifactorial, with the development of CV risk factors mediated by a combination of
233 lifestyle factors and vascular and metabolic dysfunction.

234

235 Accordingly, understanding the role of traditional risk factors is crucial for evaluating
236 cardiovascular outcomes in this population. Hypertension is a strong CVD risk factor for
237 premature mortality in women¹⁸ and women who have a history of hypertensive disorder of
238 pregnancy have an increased risk of developing hypertension¹⁹. In turn this relationship

239 mediates the association with both HF and CAD in this patient group. Similarly,
240 hyperlipidaemia is the driving factor of CHD development, without which the disease would
241 not manifest.²⁰ These patterns were evident in our study where hypertension emerged as the
242 strongest contributor to an increased risk of HF, arrhythmia and ischemic stroke; while
243 dyslipidaemia was the primary predictor of the risk of incident CHD, compared to other risk
244 factors (Figure 2-5). These findings underscore the multifaceted nature of CVD and the
245 importance of awareness of both traditional and novel risk factors to improve cardiovascular
246 outcomes in this population. Emerging evidence suggest that optimal dosing of guideline
247 directed medical therapy may differ for women²¹ and less women receive guideline directed
248 therapy²². While we were unable to evaluate the usage of cardioprotective therapy in our
249 study, our finding suggests a multi-dimensional approach is required to attenuate the
250 increased risk of CVD.

251
252 This is the first study to our knowledge that has evaluated whether lifestyle factors influence
253 CVD outcomes in women with novel risk factors. There is strong rationale for the promotion
254 of physical activity to all women to mitigate CVD risk, but individuals with increased risk
255 may benefit from more tailored intervention. Interestingly current physical activity guidelines
256 are largely derived from studies of males²³ and despite the growing understanding of sex and
257 gender specific differences in responses to exercise^{24,25}. there are no specific physical activity
258 recommendations for healthy women, nor women with a high CVD risk. Therefore, studies
259 that focus specifically on women and evaluate higher risk groups of women are essential to
260 determine the relevance and effectiveness of current physical activity guideline and their
261 effectiveness in preventing CVD. In this cohort we found that higher levels of physical
262 activity lowered the risk of HF and arrhythmia incidence in women with novel risk factors.
263 After adjusting for other confounders only the higher level of physical activity was protective

264 for women developing HF. This is consistent with meta-analysis that reported that higher
265 levels of physical activity are required to prevent HF²⁶. Conversely, in our adjusted models
266 both moderate and higher levels of physical activity lowered the risk of arrhythmia, which is
267 also consistent with prior findings demonstrating that more physically activity individuals
268 have a lower risk of arrhythmia²⁷ .

269

270 Previous studies have established the protective effects of physical activity on various
271 cardiovascular outcomes. High levels of physical activity have consistently been associated
272 with a significantly reduced risk of incident HF, with research indicating a 35% lower risk
273 among individuals with the highest level of physical activity (four times guidelines
274 recommended level), compared to a low levels.²⁸ We demonstrated that a high level of
275 physical activity (achieving ≥ 3000 MET-min/week through a combination of different
276 intensities of physical activity) is protective against developing HF, compared to a low level
277 of physical activity. On the other hand, our data showed both moderate (≥ 600 MET-
278 min/week) and high levels of physical activity attenuate the risk of arrhythmia. Observing a
279 non-linear relationship, our findings demonstrated that a moderate level of physical activity
280 was the optimal level to prevent developing arrhythmia and no further significant risk
281 reduction was achieved in women with a high level of physical activity, compared to those
282 with a moderate level. This finding has also been observed elsewhere²⁹. In contrast, a study
283 from Azarbal et al., focusing on the data of nearly 82,000 postmenopausal women without a
284 history of AF, observed a significant inverse association between a high level of recreational
285 physical activity (> 9 MET-h/week) and risk of incident AF³⁰. Variations in study population,
286 domains of physical activity (recreational vs all domains) and different confounding factors
287 might be the reason of having varied findings among the studies.

288

289 Interestingly, for CHD and stroke, no significant associations were observed after adjusting for
290 potential confounding factors. While prior studies have observed that moderate³¹ and high³²
291³³ levels of physical activity attenuate the risk of incident CHD and stroke, our findings with a
292 follow up of 13 years do not support this. It is possible that the discrepancy in findings with
293 prior work is due to the shorter follow up in our study and difficulty in identifying patients
294 with CHD or stroke prior to experiencing an event. For example, an arrhythmia can be
295 detected through ECG screening, while an exercise or pharmacological stress test would be
296 required to detect CHD and this is not routinely performed in HD and this is not routinely
297 performed in *asymptomatic* people. Whereas, Hummel et al. found that higher levels of total
298 physical activity (MET-h/day > 3.6) in women had a significantly lower risk of experiencing
299 a myocardial infarction, compared to a low level of physical activity (MET-h/day ≤ 1.6)³².
300 Apart from differences in study population, variations in the measurement of physical activity
301 further complicate comparison between the studies.

302

303 The cardiovascular benefits of physical activity are largely due to the beneficial effects on
304 CVD risk factors e.g. hypertension, dyslipidaemia, glycaemic control and optimal body
305 composition, however, some of the mechanisms of benefits are yet to be determined³⁴.
306 Sustaining higher levels of physical activity over a lifetime is likely to have provide critical
307 cardioprotection for maintaining cardiovascular health women. Indeed, we have shown in
308 women who initiate exercise training in early and mid-life, prior to menopause that exercise
309 training reduces ventricular stiffness and improves cardiorespiratory fitness^{25,35} whereas
310 other evidence suggests that cardiovascular benefits are blunted in women who increase
311 physical activity levels after menopause³⁶. Importantly women with a lifelong history of
312 increased physical activity, consistent with the levels observed to be protective in this cohort
313 of women with novel risk factors, had superior cardiac function and cardiorespiratory fitness

314 than similar aged and younger sedentary women³⁷. Physical activity can also contribute to
315 lowering CVD risk, through better metabolic health with improved insulin sensitivity and
316 glycaemic control³⁸, and better body composition³⁹. The consequential impacts of which
317 decreases the risk of increased adiposity which has been shown to directly increase
318 inflammation and alter autonomic tone, thereby raising the risk of AF^{26,30,40} and HF⁴¹.

319

320 **Strengths and limitations**

321 To our knowledge, this is the first and largest study to assess the interaction between physical
322 activity and risk of incident CVD in women with novel risk factors; however, some
323 limitations must be acknowledged. The use of self-reported data may be subject to recall bias
324 and there is a tendency to overestimate physical activity levels. We chose to evaluate total
325 physical activity levels to reflect the overall weekly behaviour, recognising that for women in
326 particular physical activity may be performed outside of structured settings. Physical activity
327 behaviour was only assessed at baseline in our study, and therefore there may have been
328 important changes to physical activity during follow-up that could have influenced our
329 findings. Menopause history was also reported by self-report. Furthermore, while we adjusted
330 our results for several key CVD risk factors, other risk factors, including female specific such
331 as preterm delivery, intrauterine growth restriction and small for gestational age, or other risk
332 factors including diet, sleeping habits and sedentary behaviour should be considered in future
333 research. Further, the UK Biobank cohort may not be reflective of the general population,
334 however there is greater than 50% participation from women which strengthens the
335 generalisability for the focus of this study. Finally, in future studies it would be important to
336 understand how novel risk factors contribute to different subtypes of HF e.g. heart failure
337 with preserved ejection fraction which is 2-fold more common in women⁴² and what effects
338 physical activity have in these populations.

339

340 CONCLUSION

341 Our study highlights the effect of novel risk factors on CVD outcomes in women, while also
342 presenting the protective effect of physical activity, specifically on incident HF and
343 arrhythmia. We showed that guideline recommended physical activity levels of 150 minutes
344 of moderate-vigorous physical activity or > 3000 met-minutes per week can prevent
345 arrhythmia; however, to achieve the maximum protective benefit of physical activity against
346 HF, women with novel risk factors need to engage in physical activity at twice the
347 recommended levels. These findings reinforce the critical role of physical activity in
348 mitigating cardiovascular risks and underscores the importance of educational campaigns
349 designed for women with a history of novel risk factors to inform women about the potential
350 benefits of physical activity and encourage them to be active. Moreover, our findings
351 highlight the need for more precise guidelines regarding the optimal level of physical activity
352 to effectively reduce the risk of incident CVD, specifically in this population.

353

354 DECLARATIONS

355 **Authors' Disclosures of Potential Conflicts of Interest.** All other authors have no relevant
356 financial or non-financial interests to disclose.

357 **Data Sharing Statement.** This research was conducted using the UK Biobank Resource
358 (<http://www.ukbiobank.ac.uk/>) under application 55469. Data from the UK Biobank is
359 accessible to eligible researchers via applying to www.ukbiobank.ac.uk.

360 **Funding Sources.** EJH was supported by an Australian National Heart Foundation Future
361 Leader Fellowship (ID: 102536).

362 Author Contributions.

363 Conception and design: EJH, LW, SRC

- 364 Collection and assembly of data: ZA
- 365 Data analysis and interpretation: ZA, EJH, LW, SRC
- 366 Manuscript writing: ZA (initial draft), All authors (revisions)
- 367 Final approval of manuscript: All authors
- 368 Accountable for all aspects of the work: All authors
- 369

370 References

- 371 1. Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, Guerrero
372 M, Kunadian V, Lam CSP, Maas A, et al. The Lancet women and cardiovascular
373 disease Commission: reducing the global burden by 2030. *Lancet*. 2021;397:2385-
374 2438. doi: 10.1016/s0140-6736(21)00684-x
- 375 2. Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular Disease in
376 Women: Clinical Perspectives. *Circ Res*. 2016;118:1273-1293. doi:
377 10.1161/circresaha.116.307547
- 378 3. Sattar N, Rawshani A, Franzén S, Rawshani A, Svensson AM, Rosengren A, McGuire
379 DK, Eliasson B, Gudbjörnsdóttir S. Age at Diagnosis of Type 2 Diabetes Mellitus and
380 Associations With Cardiovascular and Mortality Risks. *Circulation*. 2019;139:2228-
381 2237. doi: 10.1161/circulationaha.118.037885
- 382 4. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart
383 disease in women compared with men: a systematic review and meta-analysis of
384 prospective cohort studies. *Lancet*. 2011;378:1297-1305. doi: 10.1016/s0140-
385 6736(11)60781-2
- 386 5. Roa-Díaz ZM, Raguindin PF, Bano A, Laine JE, Muka T, Glisic M. Menopause and
387 cardiometabolic diseases: What we (don't) know and why it matters. *Maturitas*.
388 2021;152:48-56. doi: 10.1016/j.maturitas.2021.06.013
- 389 6. Täufer Cederlöf E, Lundgren M, Lindahl B, Christersson C. Pregnancy Complications
390 and Risk of Cardiovascular Disease Later in Life: A Nationwide Cohort Study. *J Am*
391 *Heart Assoc*. 2022;11:e023079. doi: 10.1161/jaha.121.023079
- 392 7. Khan SS, Petito LC, Huang X, Harrington K, McNeil RB, Bello NA, Bairey Merz
393 CN, Miller EC, Ravi R, Scifres C, et al. Body Mass Index, Adverse Pregnancy
394 Outcomes, and Cardiovascular Disease Risk. *Circ Res*. 2023;133:725-735. doi:
395 10.1161/circresaha.123.322762
- 396 8. El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD,
397 Limacher MC, Manson JE, Stefanick ML, Allison MA, et al. Menopause Transition
398 and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A
399 Scientific Statement From the American Heart Association. *Circulation*.
400 2020;142:e506-e532. doi: 10.1161/CIR.0000000000000912
- 401 9. Ekelund U, Steene-Johannessen J, Brown WJ, Fagerland MW, Owen N, Powell KE,
402 Bauman A, Lee IM. Does physical activity attenuate, or even eliminate, the
403 detrimental association of sitting time with mortality? A harmonised meta-analysis of
404 data from more than 1 million men and women. *Lancet*. 2016;388:1302-1310. doi:
405 10.1016/s0140-6736(16)30370-1
- 406 10. Ekelund U, Brown WJ, Steene-Johannessen J, Fagerland MW, Owen N, Powell KE,
407 Bauman AE, Lee IM. Do the associations of sedentary behaviour with cardiovascular
408 disease mortality and cancer mortality differ by physical activity level? A systematic
409 review and harmonised meta-analysis of data from 850 060 participants. *Br J Sports*
410 *Med*. 2019;53:886-894. doi: 10.1136/bjsports-2017-098963
- 411 11. Chen LJ, Hamer M, Lai YJ, Huang BH, Ku PW, Stamatakis E. Can physical activity
412 eliminate the mortality risk associated with poor sleep? A 15-year follow-up of
413 341,248 MJ Cohort participants. *J Sport Health Sci*. 2021. doi:
414 10.1016/j.jshs.2021.03.001
- 415 12. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P,
416 Green J, Landray M, et al. UK biobank: an open access resource for identifying the
417 causes of a wide range of complex diseases of middle and old age. *PLoS Med*.
418 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779

- 419 13. International Physical Activity Questionnaire.
420 <https://sites.google.com/view/ipaq/score>.
- 421 14. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt
422 M, Ekelund U, Yngve A, Sallis JF. International physical activity questionnaire: 12-
423 country reliability and validity. *Medicine & science in sports & exercise*.
424 2003;35:1381-1395.
- 425 15. Zhu D, Chung HF, Dobson AJ, Pandeya N, Giles GG, Bruinsma F, Brunner EJ, Kuh
426 D, Hardy R, Avis NE, et al. Age at natural menopause and risk of incident
427 cardiovascular disease: a pooled analysis of individual patient data. *Lancet Public
428 Health*. 2019;4:e553-e564. doi: 10.1016/s2468-2667(19)30155-0
- 429 16. Yoshida Y, Chen Z, Baudier RL, Krousel-Wood M, Anderson AH, Fonseca VA,
430 Mauvais-Jarvis F. Early Menopause and Cardiovascular Disease Risk in Women With
431 or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women.
432 *Diabetes Care*. 2021;44:2564-2572. doi: 10.2337/dc21-1107
- 433 17. Parikh NI, Gonzalez JM, Anderson CAM, Judd SE, Rexrode KM, Hlatky MA,
434 Gunderson EP, Stuart JJ, Vaidya D, Epidemiology ObotAHACo, et al. Adverse
435 Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for
436 Cardiovascular Disease Prevention in Women: A Scientific Statement From the
437 American Heart Association. *Circulation*. 2021;143:e902-e916. doi:
438 doi:10.1161/CIR.0000000000000961
- 439 18. Gerds E, Sudano I, Brouwers S, Borghi C, Bruno RM, Ceconi C, Cornelissen V,
440 Diévarf F, Ferrini M, Kahan T, et al. Sex differences in arterial hypertension: A
441 scientific statement from the ESC Council on Hypertension, the European Association
442 of Preventive Cardiology, Association of Cardiovascular Nursing and Allied
443 Professions, the ESC Council for Cardiology Practice, and the ESC Working Group
444 on Cardiovascular Pharmacotherapy. *European Heart Journal*. 2022;43:4777-4788.
445 doi: 10.1093/eurheartj/ehac470
- 446 19. Honigberg MC, Zekavat SM, Aragam K, Klarin D, Bhatt DL, Scott NS, Peloso GM,
447 Natarajan P. Long-Term Cardiovascular Risk in Women With Hypertension
448 During Pregnancy. *Journal of the American College of Cardiology*. 2019;74:2743-
449 2754. doi: doi:10.1016/j.jacc.2019.09.052
- 450 20. Sallam T, Watson KE. Predictors of cardiovascular risk in women. *Womens Health
451 (Lond)*. 2013;9:491-498. doi: 10.2217/whe.13.44
- 452 21. Agarwal A, Peters SAE, Chandramouli C, Lam CSP, Figtree GA, Arnott C. Guideline-
453 Directed Medical Therapy in Females with Heart Failure with Reduced Ejection
454 Fraction. *Curr Heart Fail Rep*. 2021;18:284-289. doi: 10.1007/s11897-021-00524-z
- 455 22. Sumarsono A, Xie L, Keshvani N, Zhang C, Patel L, Alonso WW, Thibodeau JT,
456 Fonarow GC, Van Spall HGC, Messiah SE, et al. Sex Disparities in Longitudinal Use
457 and Intensification of Guideline-Directed Medical Therapy Among Patients With
458 Newly Diagnosed Heart Failure With Reduced Ejection Fraction. *Circulation*.
459 2024;149:510-520. doi: 10.1161/circulationaha.123.067489
- 460 23. Blair SN, LaMonte MJ, Nichaman MZ. The evolution of physical activity
461 recommendations: how much is enough?1234. *The American Journal of Clinical
462 Nutrition*. 2004;79:913S-920S. doi: <https://doi.org/10.1093/ajcn/79.5.913S>
- 463 24. Bassareo PP, Crisafulli A. Gender Differences in Hemodynamic Regulation and
464 Cardiovascular Adaptations to Dynamic Exercise. *Curr Cardiol Rev*. 2020;16:65-72.
465 doi: 10.2174/1573403x15666190321141856
- 466 25. Barnes JN, Fu Q. Sex-Specific Ventricular and Vascular Adaptations to Exercise. *Adv
467 Exp Med Biol*. 2018;1065:329-346. doi: 10.1007/978-3-319-77932-4_21

- 468 26. Aune D, Schlesinger S, Leitzmann MF, Tonstad S, Norat T, Riboli E, Vatten LJ.
469 Physical activity and the risk of heart failure: a systematic review and dose-response
470 meta-analysis of prospective studies. *Eur J Epidemiol.* 2021;36:367-381. doi:
471 10.1007/s10654-020-00693-6
- 472 27. Elliott AD, Linz D, Mishima R, Kadhim K, Gallagher C, Middeldorp ME, Verdicchio
473 CV, Hendriks JML, Lau DH, La Gerche A, et al. Association between physical
474 activity and risk of incident arrhythmias in 402 406 individuals: evidence from the
475 UK Biobank cohort. *European Heart Journal.* 2020;41:1479-1486. doi:
476 10.1093/eurheartj/ehz897
- 477 28. Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, Mayo HG, de
478 Lemos JA, Berry JD. Dose-Response Relationship Between Physical Activity and
479 Risk of Heart Failure: A Meta-Analysis. *Circulation.* 2015;132:1786-1794. doi:
480 10.1161/circulationaha.115.015853
- 481 29. Jin MN, Yang PS, Song C, Yu HT, Kim TH, Uhm JS, Sung JH, Pak HN, Lee MH,
482 Joung B. Physical Activity and Risk of Atrial Fibrillation: A Nationwide Cohort Study
483 in General Population. *Sci Rep.* 2019;9:13270. doi: 10.1038/s41598-019-49686-w
- 484 30. Azarbal F, Stefanick ML, Salmoirago-Blotcher E, Manson JE, Albert CM, LaMonte
485 MJ, Larson JC, Li W, Martin LW, Nassir R, et al. Obesity, physical activity, and their
486 interaction in incident atrial fibrillation in postmenopausal women. *J Am Heart Assoc.*
487 2014;3. doi: 10.1161/jaha.114.001127
- 488 31. Armstrong ME, Green J, Reeves GK, Beral V, Cairns BJ. Frequent physical activity
489 may not reduce vascular disease risk as much as moderate activity: large prospective
490 study of women in the United Kingdom. *Circulation.* 2015;131:721-729. doi:
491 10.1161/circulationaha.114.010296
- 492 32. Hummel M, Hantikainen E, Adami HO, Ye W, Belloc R, Bonn SE, Lagerros YT.
493 Association between total and leisure time physical activity and risk of myocardial
494 infarction and stroke - a Swedish cohort study. *BMC Public Health.* 2022;22:532. doi:
495 10.1186/s12889-022-12923-5
- 496 33. Sattelmair JR, Kurth T, Buring JE, Lee IM. Physical activity and risk of stroke in
497 women. *Stroke.* 2010;41:1243-1250. doi: 10.1161/strokeaha.110.584300
- 498 34. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of
499 cardiovascular events: potential mediating mechanisms. *Circulation.* 2007;116:2110-
500 2118. doi: 10.1161/circulationaha.107.729939
- 501 35. Howden EJ, Sarma S, Lawley JS, Opondo M, Cornwell W, Stoller D, Urey MA,
502 Adams-Huet B, Levine BD. Reversing the Cardiac Effects of Sedentary Aging in
503 Middle Age-A Randomized Controlled Trial: Implications For Heart Failure
504 Prevention. *Circulation.* 2018;137:1549-1560. doi:
505 10.1161/circulationaha.117.030617
- 506 36. Seals DR, Nagy EE, Moreau KL. Aerobic exercise training and vascular function with
507 ageing in healthy men and women. *J Physiol.* 2019;597:4901-4914. doi:
508 10.1113/jp277764
- 509 37. Carrick-Ranson G, Howden EJ, Brazile TL, Levine BD, Reading SA. Effects of aging
510 and endurance exercise training on cardiorespiratory fitness and cardiac structure and
511 function in healthy midlife and older women. *Journal of Applied Physiology.*
512 2023;135:1215-1235. doi: 10.1152/jappphysiol.00798.2022
- 513 38. Thyfault JP, Bergouignan A. Exercise and metabolic health: beyond skeletal muscle.
514 *Diabetologia.* 2020;63:1464-1474. doi: 10.1007/s00125-020-05177-6
- 515 39. Westerterp KR. Exercise, energy balance and body composition. *European Journal of*
516 *Clinical Nutrition.* 2018;72:1246-1250. doi: 10.1038/s41430-018-0180-4

- 517 40. Ofman P, Khawaja O, Rahilly-Tierney CR, Peralta A, Hoffmeister P, Reynolds MR,
518 Gaziano JM, Djousse L. Regular physical activity and risk of atrial fibrillation: a
519 systematic review and meta-analysis. *Circ Arrhythm Electrophysiol*. 2013;6:252-256.
520 doi: 10.1161/circep.113.000147
- 521 41. Lopez-Jimenez F, Almahmeed W, Bays H, Cuevas A, Di Angelantonio E, le Roux
522 CW, Sattar N, Sun MC, Wittert G, Pinto FJ, et al. Obesity and cardiovascular disease:
523 mechanistic insights and management strategies. A joint position paper by the World
524 Heart Federation and World Obesity Federation. *European Journal of Preventive
525 Cardiology*. 2022;29:2218-2237. doi: 10.1093/eurjpc/zwac187
- 526 42. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R,
527 Killian JM, Roger VL. A Contemporary Appraisal of the Heart Failure Epidemic in
528 Olmsted County, Minnesota, 2000 to 2010. *JAMA Internal Medicine*. 2015;175:996-
529 1004. doi: 10.1001/jamainternmed.2015.0924
- 530
- 531

532 **Table 1. Participants Characteristics**

	Novel risk factors (N=55930)	Without novel risk factors (N=197370)
General Characteristics		
Age at baseline (year)	57.3 ± 7.6	55.8 ± 8.0
Ethnicity, n (%)		
White	52209 (93.3)	186,747 (94.6)
Asian	1362 (2.4)	3686 (1.9)
Black	1164 (2.1)	3033 (1.5)
Others	1195 (2.2)	3904 (2.0)
Risk factors		
Smoker, n (%)	31,745 (56.7)	106623 (54.0)
BMI (kg/m ²)	27.4 ± 5.2	26.8 ± 5.0
Obesity, n (%)	14431 (25.8)	43345 (21.9)
Glucose (mmol/L)	5.1 ± 1.1	5.0 ± 0.99
HbA1c (mmol/mol)	36.3 ± 6.4	35.5 ± 5.6
Diabetes Mellitus, n (%)	4536 (8.1)	10150 (5.1)
SBP (mmHg)	138 ± 20	137 ± 20
DBP (mmHg)	81 ± 10	81 ± 10
Hypertension, n (%)	16,846 (30.1)	45590 (23.0)
Total cholesterol (mmol/L)	4.8 ± 0.9	4.7 ± 0.9
LDL cholesterol (mmol/L)	1.8 ± 0.4	1.7 ± 0.4
HDL cholesterol (mmol/L)	1.4 ± 0.3	1.4 ± 0.3
Total triglyceride (mmol/L)	1.3 ± 0.6	1.2 ± 0.5
Dyslipidaemia, n (%)	7635 (13.6)	19096 (9.6)
Cancer, n (%)	10272 (18.3)	32691 (16.5)
Physical Activity		
Summed PA (MET-min/wk)	2611 ± 2575.0	2495 ± 2437.3
	Low	7986 (14.3)
IPAQ n (%)	Moderate	18235 (32.6)
	High	17101 (30.6)
	Missing	12608 (22.5)

533

534 Acronyms: BMI: Body mass index, HbA1c: Haemoglobin A1c, SBP: Systolic blood
535 pressure, DBP: Diastolic blood pressure, LDL: Low-density lipoprotein, HDL: High-density
536 lipoprotein, HRT: Hormone replacement therapy, OCP: Oral contraceptive pills, POP:
537 Progestogen-only pills, PA: Physical activity, IPAQ: International physical activity
538 questionnaire.
539
540

541 **Table 2. Incidence of CVD Events in women with and without novel risk factors**

	Novel risk factors	Without novel risk factors
	(N=55930)	(N=197370)
Heart Failure, n (%)	1374 (2.4)	3318 (1.7)
Arrhythmia, n (%)	2699 (4.8)	7104 (3.5)
Coronary Heart Disease, n (%)	3963 (6.6)	9449 (4.7)
Ischemic stroke, n (%)	797 (1.4)	1933 (0.9)

542

543

544